PURDUE PHARMA, LP for PURDUE PHARMA LP
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Monitored congressional activity relating to coverage requirements, employer healthcare-related issues, and public health matters relating to pandemic preparedness and response.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN KONKA New | — |
Alcohol and Drug Abuse ALC
Monitored activity on bills that seek to improve access to substance use disorder treatment by removing certain barriers to care.: H.R. 1384 - Mainstreaming Addiction Treatment Act of 2021, H.R. 4203 IMPROVE Addiction Care Act, and H.R. 955 / S. 285 Medicaid Reentry Act of 2021.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN KONKA | — |
Bankruptcy BNK
Monitored ongoing congressional activity pertaining to bankruptcy reforms and use of non-debtor releases in bankruptcy (H.R. 2096 / S. 2472 and H.R. 4777 / 2497), including outreach regarding committee hearings held on these issues and potential future hearings and activity on the legislation.
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN KONKA | — |
Medicare/Medicaid MMM
Monitored congressional activity on legislation to address prescription drug prices in the Medicare and Medicaid programs (H.R. 19 - Lower Costs, More Cures Act of 2021, and H.R. 3 - Elijah E. Cummings Lower Drug Costs Now Act).
| Lobbyist | Covered position, as disclosed |
|---|---|
| KATHLEEN KONKA | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.